Recent advances in therapeutic drugs and vaccines against Ebola virus

VernacularTitle:埃博拉病毒及治疗药物和疫苗的研究进展
Author: Xi MA ; Jia YAO ; Changbin CHAI ; Hong ZHANG ; Yang WANG
Publication Type:Journal Article
Keywords: Ebola virus; Ebola hemorrhagic fever; Therapeutic drug; Vaccine; Research and de-velopment
From: Chinese Journal of Microbiology and Immunology 2016;36(5):390-395
CountryChina
Language:Chinese
Abstract: Ebola hemorrhagic fever is an acute infectious disease caused by Ebola virus,the mor-tality rate of which is up to 90% . Due to its high infection rate,high mortality rate as well as being a serious threat to public health and safety,Ebola virus is listed as a World Health Organization Risk Group 4 Patho-gen(requiring Biosafety Level 4-equivalent containment). However,there is no effective control method and treatment for Ebola virus infection. Different approaches have been used to develop vaccines and therapeutic drugs against Ebola virus infection and clinical trials of some products have been initiated,such as ZMapp, BCX-4430,GS-5734,DNA vaccines,and adenovirus vector vaccines. National Institutes of Health(NIH) announced a successful development of vaccine for Ebola virus which had passed the clinical trial by the end of 2014. At the meantime,the first anti-Ebola virus medicine had also been approved in China for emergency use only. Recent advances in the research and development of therapeutic drugs and vaccines against Ebola virus will be described in this review.